Overall Survival statistical summary

VariableTotalUnivariate Cox modelsMultivariate Cox models
Clinical modelClinical and CD8 modelClinical and HLA modelClinical and HLA/CD8 model
Hratio95% ICpadj padj padj pHratio95% ICpadj padj padj pHratio95% ICpadj padj padj pHratio95% ICpadj padj padj pHratio95% ICpadj padj padj p
Age (%)median (range)63 (29–83)1.015[0.993;1.038]0.180.421.018[0.995;1.041]0.130.361.012[0.990;1.035]0.30.571.016[0.993;1.040]0.170.421.015[0.993;1.039]0.180.42
continuousmean(sd)61.73 (11.47)
Sex(%)Female33 (28.95)11111
Male81 (71.05)0.762[0.469;1.238]0.270.550.77[0.464;1.282]0.320.570.771[0.460;1.292]0.320.570.759[0.447;1.289]0.310.570.686[0.397;1.185]0.180.42
Chemo(%)No36 (31.58)11111
Yes78 (68.42)0.812[0.502;1.314]0.40.60.73[0.432;1.231]0.240.530.928[0.534;1.612]0.790.920.744[0.438;1.262]0.270.550.793[0.464;1.355]0.40.6
KRASNo79 (69.30)1
Yes35 (30.70)1.979[1.211;3.233]0.0060.05
BRAF+KRASNo76 (66.67)11111
Yes38 (33.33)1.737[1.07;2.82]0.030.132.06[1.223;3.487]0.0070.052.171[1.281;3.682]0.0040.051.882[1.104;3.230]0.020.11.716[0.992;2.968]0.050.2
Tumor sideRight25 (21.93)111111
Left89 (78.07)0.92[0.528;1.604]0.770.911.304[0.721;2.359]0.380.61.151[0.639;2.074]0.640.791.334[0.735;2.421]0.340.581.208[0.671;2.175]0.530.7
CD8 invasive margin continuous0.66[0.500;0.866]0.0030.050.644[0.477;0.869]0.0040.05
CD8 tumor core continuous0.906[0.679;1.209]0.50.67
CD8 total continuous0.705[0.534;0.926]0.010.06
HLA score41 (37.27)11
69 (62.73)0.593[0.366;0.959]0.030.130.631[0.379;1.050]0.080.25
HLA/CD8 combinedLow/Low24 (21.82)11
Others86 (78.18)0.391[0.230;0.663]0.00050.020.415[0.234;0.737]0.0030.05
PDL1 TC SP142High181
Low5 (4.39)0.6[0.147;2.443]0.480.66
PDL1 invasive margin SP142High34 (29.82)1
Low80 (70.18)0.791[0.463;1.348]0.390.6
CD163 invasive margin127 (23.68)1
242 (36.84)0.719[0.408;1.266]0.250.54
332 (28.07)0.807[0.443;1.467]0.480.66
FoxP3 invasive margin045 (39.47)1
120 (17.54)1.182[0.654;2.135]0.580.73
NKp46Low50 (49.50)1
High45 (50.50)1.024[0.640;1.636]0.930.98
AUC0.630.720.670.72